Effects of ligustrazine controlled release capsule in chronic pulmonary heart disease.
Before and after oral administration of ligustrazine controlled release capsule, pulmonary hemodynamics, right cardiac function, arterial blood gas and TXB2/6-keto-PGF1 alpha were studied in 16 patients with advanced cor pulmonale. The decrease of pulmonary arterial pressure and pulmonary vascular resistance, increase of cardiac output, improvement of right cardiac function and arterial blood gas were demonstrated after one course of treatment. The mechanism of these effects may be related to improvement of imbalance of TXB2/6-keto-PGF1 alpha. These results were in agreement with those of intravenous administration of ligustrazine, but no adverse reactions were found.
Peng
W
W
Department of Internal Medicine, Tongji Hospital, Tongji Medical University, Wuhan.
Duan
S F
SF
D000284:Administration, Oral; D000368:Aged; D002214:Capsules; D003692:Delayed-Action Preparations; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011652:Pulmonary Circulation / Q000187:drug effects*; D011660:Pulmonary Heart Disease / Q000188:drug therapy* / Q000503:physiopathology; D011719:Pyrazines / Q000008:administration & dosage*; D014665:Vasodilator Agents / Q000008:administration & dosage*
D002214:Capsules; D003692:Delayed-Action Preparations; D011719:Pyrazines; D014665:Vasodilator Agents; C017953:tetramethylpyrazine